Natera (NASDAQ: NTRA) reported third-quarter 2026 revenue of $794 million, up 34.1% year on year and above analysts' estimate of $709.3 million. Its GAAP loss of $0.42 per share was wider than the expected $0.27 loss. The genetic testing company raised its full-year revenue guidance to $3.02 billion at the midpoint, from $2.88 billion. Operating margin improved to -8.6% from -16.5%, while gross margin rose to 65%. Clinical MRD testing volumes grew 56%, and organ health volumes rose nearly 40%. Steve Chapman stepped down as chief executive officer and will stay on as an adviser. Successor Solomon Moshkevich set a goal of $6 billion in revenue in 2029. Higher spending on research, clinical trials and pharma services widened the loss. Shares fell to $303.50 from $363.76 before the results.

What Natera (NTRA) said on its Q3 earnings call. Natera (NASDAQ:NTRA) raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership. Steve Chapman is stepping down as chief executive officer and handing the role to Solomon Moshkevich, a longtime Natera executive who helped build its oncology business. Chapman said he will remain with the company as a consultant and adviser to the board. Moshkevich said he does not expect a major shift in strategy. "You are not going to see any big radical change," he told analysts on the Nov. 5 earnings call, adding that the company will remain focused on customer service, clinical data and product development. Revenue and test volumes rise. Third-quarter revenue rose to $794 million from $592 million a year earlier. Excluding revenue true-ups, growth was 42%, Moshkevich said. True-ups fell to approximately $32 million from $52 million in the second quarter as Natera incorporated some recent average selling price gains into its revenue accruals, Chief Financial Officer Michael Brophy said. Natera processed approximately 1.1 million tests during the quarter, up more than 22% from about 894,000 a year earlier. Clinical molecular residual disease, or MRD, volumes reached approximately 316,000 units, an increase of 56%. Those tests include Signatera and Latitude MRD. Moshkevich said growth reflected new accounts, new patient starts and repeat testing. Colorectal and breast cancer remained the largest indications, although the company also saw growth across other cancer types. The average selling price for Signatera increased to approximately $1,290 from $1,271 in the second quarter. Natera reported gross margin of about 65%; excluding true-ups, gross margin rose to 63.2%, an increase of roughly 140 basis points from the prior quarter. The company said it generated cash and narrowed its losses but did not provide a loss figure on the call. Higher outlook and 2029 revenue goal. Natera raised its 2026 revenue guidance to $3.005 billion to $3.035 billion from $2.85 billion to $2.91 billion. The new midpoint is $140 million higher. Brophy said the forecast assumes steady average selling prices and continued volume growth but excludes any fourth-quarter true-ups. The company maintained its full-year gross margin outlook of 64% to 66%. It also raised the top end of its research and development expense range by $25 million and increased the upper end of its selling, general and administrative expense outlook to $1.3 billion from $1.225 billion. Brophy cited investment in pharma services and clinical trials, along with legal expenses and spending on commercial initiatives. For 2027, Brophy said preliminary planning assumptions include operating expense growth of 10% to 12% and a gross margin range similar to the 2026 outlook. He said Natera expects to remain cash flow generative while investing in MRD and early cancer detection trials. Moshkevich also set a goal of doubling annual revenue to $6 billion by 2029, with profitability expected if the company executes its plan. He said the target relies primarily on existing businesses and assumes only a small contribution from emerging cancer screening products. He added that Natera could reach the goal without Signatera's average selling price rising much beyond $1,450, though management sees potential upside. Coverage, Japan and pharma demand. Medicare has granted coverage for serial Signatera testing in the surveillance of patients with early-stage hepatocellular carcinoma, a form of liver cancer. Moshkevich said the decision followed roughly a year of work with MolDX, the Medicare program that evaluates molecular diagnostic tests. Brophy said Natera has nine or 10 additional MolDX submissions in progress. Moshkevich said the company could not predict their timing or order. In Japan, Natera is preparing to launch Signatera for colorectal and muscle-invasive bladder cancer after receiving regulatory approval for the latter indication in the third quarter. The company is discussing reimbursement and pricing for both indications with Japan's health ministry and expects an update by the JPMorgan Healthcare Conference, if not sooner. Moshkevich said biopharma demand for MRD technology has accelerated: revenue from the first three quarters of 2026 was roughly 70% higher than pharma revenue for all of 2025. He said the company's 2029 target would require several hundred million dollars of contribution from pharma and data services. Clinical studies and early detection. Chief Medical Officer Alex Aleshin said Natera is completing an upgrade to Signatera Genome that incorporates phase and structural variants. The company expects the technology to feature in additional studies and pharma partnerships. Aleshin highlighted early findings from the ongoing SAGITTARIUS colon cancer trial. Among the first 205 patients in the physician's choice arm, one in three had an adjuvant treatment plan changed after a negative Signatera result, and 87% of those changes reduced treatment intensity. He noted that the trial's primary readout is still several years away. Natera completed enrollment in the third quarter for the premarket approval cohort of its FIND early cancer detection study, with 30,000 patients. Aleshin said the company is working toward a definitive colorectal cancer readout in 2027. Separately, the Food and Drug Administration granted breakthrough device designation in October to Natera's multi-cancer early detection assay, he said. About Natera (NASDAQ:NTRA). Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals. In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

Natera (NASDAQ:NTRA) releases earnings results, misses expectations by $0.14 EPS. Natera (NASDAQ:NTRA - Get Free Report) posted its quarterly earnings data on Thursday. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14), FiscalAI reports. The company had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative return on equity of 8.73% and a negative net margin of 5.66%. The business's revenue for the quarter was up 34.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.64) EPS. Here are the key takeaways from Natera's conference call: * Natera reported a record quarter, processing about 1.09 million tests, up 22%, and generating $794 million in revenue, up 34% year over year - or more than 40% excluding revenue true-ups. Clinical MRD volumes rose 56% to approximately 316,000 units. * The company raised its 2026 revenue guidance to $3.005 billion-$3.035 billion, an increase of $140 million at the midpoint. It also reported 65% gross margin and said losses narrowed while it generated cash. * Management highlighted new Medicare coverage for Signatera surveillance in early-stage liver cancer, nine to ten additional MolDX submissions in progress, and plans to launch colorectal and bladder cancer testing in Japan pending reimbursement and pricing. Executives said the coverage pipeline could support further Signatera ASP growth, though timing and outcomes remain uncertain. * Natera set a goal of doubling revenue to $6 billion by 2029, primarily through continued growth in oncology testing, higher Signatera ASPs, international expansion, and pharma and data services. Management expects early cancer detection to contribute relatively little to that target in 2028-2029. * The company plans to increase investment to support clinical trials, pharma and data demand, and early cancer detection; operating expenses are expected to grow 10%-12% in 2027. Management also cautioned that newer products may weigh on near-term costs and gross margins, although it expects cost improvements over time. Natera trading down 14.6%. NTRA stock traded down $53.09 during trading hours on Friday, hitting $310.67. 5,775,619 shares of the stock traded hands, compared to its average volume of 1,711,005. The stock has a 50-day simple moving average of $380.25 and a 200 day simple moving average of $269.68. The company has a market cap of $44.78 billion, a P/E ratio of -272.52 and a beta of 1.55. Natera has a one year low of $181.00 and a one year high of $437.41. Analyst upgrades and downgrades. A number of research firms have commented on NTRA. Canaccord Genuity Group boosted their price target on shares of Natera from $375.00 to $500.00 and gave the stock a "buy" rating in a research report on Monday, October 19th. UBS Group upped their price target on shares of Natera from $290.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Royal Bank Of Canada increased their price objective on shares of Natera from $350.00 to $460.00 and gave the company an "outperform" rating in a report on Friday, September 25th. Stephens raised their price objective on shares of Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Finally, BTIG Research raised their price objective on shares of Natera from $320.00 to $430.00 and gave the company a "buy" rating in a research note on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $391.69. Insider buying and selling at Natera. In other Natera news, CEO Steven Chapman sold 3,801 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the sale, the chief executive officer directly owned 87,431 shares of the company's stock, valued at approximately $36,004,085.80. This represents a 4.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,419 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the completion of the sale, the insider directly owned 101,323 shares of the company's stock, valued at $41,519,125.71. The trade was a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 53,573 shares of company stock valued at $19,856,400 in the last ninety days. 5.05% of the stock is owned by insiders. Key headlines impacting Natera. Here are the key news stories impacting Natera this week: * Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. * Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. * JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. * CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. * The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera company profile. Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence. The company also provides Prospera, a molecular test used to help assess organ transplant rejection. Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.